Mathys Monica
(Corresponding author) Associate Professor of Pharmacy Practice, Clinical Pharmacy Specialist-Mental Health, Texas Tech University Health Sciences Center, Dallas, Texas,
Ment Health Clin. 2018 Nov 1;8(6):284-293. doi: 10.9740/mhc.2018.11.284. eCollection 2018 Nov.
Behavioral and psychological symptoms of dementia (BPSD) occur in approximately 80% of patients who receive a diagnosis of major neurocognitive disorder. Nonpharmacologic strategies are the first-line treatment for BPSD. However, psychotropic medications are often necessary when nonpharmacologic methods are not effective in treating symptoms that are distressing or are causing behaviors that are dangerous to the patient or the patient's caregivers. The article provides a review of evidence-based recommendations for the use of antipsychotics, cognitive enhancers, and serotonin reuptake inhibitors for the treatment of BPSD. Different pharmacologic approaches are demonstrated through 2 patient cases in which nonpharmacologic management was not effective. The severity of BPSD must be weighed against the risks and benefits of pharmacologic intervention in order to implement an optimal medication regimen.
痴呆的行为和心理症状(BPSD)在约80%被诊断为重度神经认知障碍的患者中出现。非药物策略是BPSD的一线治疗方法。然而,当非药物方法在治疗令人痛苦的症状或导致对患者或其护理人员有危险行为的症状方面无效时,精神药物通常是必要的。本文综述了使用抗精神病药、认知增强剂和5-羟色胺再摄取抑制剂治疗BPSD的循证推荐。通过2例非药物治疗无效的患者病例展示了不同的药物治疗方法。必须权衡BPSD的严重程度与药物干预的风险和益处,以实施最佳药物治疗方案。